查看“奥那色替”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            奥那色替(Onatasertib)，研发代码为CC-223，是由塞尔基因(Celgene)开发的一种口服、强效、具有高度选择性的<strong>[[mTOR激酶抑制剂]]</strong>。作为第二代mTOR抑制剂(TORKi)，它通过ATP竞争性机制同时抑制<strong>[[mTORC1]]</strong>和<strong>[[mTORC2]]</strong>两个复合体。与传统的雷帕霉素类似物不同，奥那色替能够有效阻断由mTORC2介导的<strong>[[AKT]]</strong>反馈性激活，从而更彻底地抑制<strong>[[PI3K/AKT/mTOR]]</strong>信号轴。该药物在临床研究中主要针对弥漫大B细胞淋巴瘤、乳腺癌及多种晚期实体瘤。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">奥那色替 (Onatasertib)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">CC-223·TORKi·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点：mTORC1/mTORC2</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2475</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P42345</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">421.5g/mol</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发代码</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">CC-223</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">ATP竞争性抑制剂</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">代谢酶</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">CYP3A4</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">研究深度</th>
                    <td style="padding: 12px; color: #b91c1c;">临床II期阶段</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：mTOR 激酶催化域的直接拦截</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        奥那色替通过与mTOR蛋白的ATP结合口袋竞争，实现了对信号瀑布的垂直封锁：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;">阻断<strong>mTORC2</strong>反馈环：第一代抑制剂仅作用于mTORC1，常引发mTORC2介导的AKT(Ser473位点)代偿性激活。奥那色替通过同时抑制mTORC2，彻底封锁了这一逃逸路径。</li>
        <li style="margin-bottom: 12px;">强化<strong>4EBP1</strong>抑制：奥那色替能更有效地降低4EBP1的磷酸化水平，从而精准调控蛋白质翻译起始。</li>
        <li style="margin-bottom: 12px;">重塑肿瘤代谢：通过双重抑制，奥那色替显著降低了肿瘤细胞的糖酵解速率及脂质合成能力。</li>
    </ul>
    

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究与证据矩阵</h2>
    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验领域</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">研究人群/方案</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键发现与结论</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">血液肿瘤</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">复发难治性非霍奇金淋巴瘤(NHL)。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">在弥漫大B细胞淋巴瘤(DLBCL)亚组中观察到显著的单药代谢缓解。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">乳腺癌</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">HR+/HER2-晚期乳腺癌；联合氟维司群。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">证明了在依维莫司耐药患者中通过TORKi实现挽救治疗的可能性。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">安全性</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">剂量递增与扩展队列分析。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">主要不良事件为<strong>高血糖</strong>、皮疹及黏膜炎症。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从生物标志物到毒性管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        奥那色替的临床应用高度依赖于精准的分子分型及系统性的副作用防控：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;">人群筛选指标：携带<strong>PIK3CA</strong>突变或<strong>PTEN</strong>蛋白缺失的实体瘤患者展现出更优的治疗响应。</li>
        <li style="margin-bottom: 12px;">代谢负面影响：抑制mTORC2会干扰胰岛素信号，诱发<strong>二型糖尿病</strong>样表现，需全程监测血糖水平。</li>
        <li style="margin-bottom: 12px;">序贯治疗逻辑：奥那色替常被探索作为第一代mTOR抑制剂耐药后的有效序贯方案。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[mTORC2]]</strong>：磷酸化AKT核心位点的激酶复合体。</li>
            <li style="margin-bottom: 8px;"><strong>[[TORKi]]</strong>：直接作用于mTOR激酶域的第二代抑制剂总称。</li>
            <li style="margin-bottom: 8px;"><strong>[[4EBP1]]</strong>：调控蛋白质翻译起始的核心效应分子。</li>
            <li style="margin-bottom: 8px;"><strong>[[反馈激活]]</strong>：单一通路抑制后诱发的代偿性信号反弹现象。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Bendell JC, et al. (2015).</strong> <em>Phase I, First-in-Human Study of CC-223, a Novel mTOR Kinase Inhibitor.</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该研究确立了奥那色替在人体中的安全性及对mTOR双重复合体的抑制活性。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>[[The Lancet Oncology]]. (2024Update).</strong> <em>Emerging TORKi Strategies in Overcoming Resistance to Rapalogs.</em> [Academic Review]<br>
            <span style="color: #475569;">[学术点评]：综述深入解析了奥那色替在阻断AKT反馈回路中的独特生物学价值。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            奥那色替 (Onatasertib) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[mTORC1]]•[[mTORC2]]•[[AKT]]•[[4EBP1]]•[[S6K1]]•[[PIK3CA]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[依维莫司]]•[[阿必利塞]]•[[氟维司群]]•[[MEK抑制剂]]•[[AZD8186]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[Celgene]]•[[BMS]]•[[SinoCellGene协助]]•[[FDA]]•[[AACR]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿驱动</td>
                <td style="padding: 10px 15px; color: #334155;">[[克服代偿性耐药]]•[[代谢重塑干预]]•[[CAR-NK序贯增敏]]•[[PROTAC降解剂]]</td>
            </tr>
        </table>
    </div>

</div>